Home LiteratureArticle Details
PMID: 18549439 Published · ppublish English Journal Article

Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Clinical and experimental immunology ·Vol. 153 ·No. 2 ·2008-08-00 ·Pages 231-9

Scherrenburg J, Piriou ER, Nanlohy NM, van Baarle D

Abstract

We studied simultaneously Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) T cell responses during and after infectious mononucleosis (IM), using a previously described 12-day stimulation protocol with EBNA1 or BZLF1 peptide pools. Effector function of EBV-specific T cells was determined after restimulation by measuring intracellular interferon-gamma production. During IM, BZLF1-specifc CD4(+) T cell responses were dominant compared with CD8(+) T cell responses. EBNA1-specific CD4(+) and CD8(+) T cell responses were low and remained similar for 6 months. However, 6 months after IM, BZLF1-specific CD4(+) T cell responses had declined, but CD8(+) T cell responses had increased. At diagnosis, EBV-specific CD8(+) T cells as studied by human leucocyte antigen class I tetramer staining comprised a tetramer(bright)CD8(bright) population consisting mainly of CD27(+) memory T cells and a tetramer(dim)CD8(dim) population consisting primarily of CD27(-) effector T cells. The remaining EBV-specific CD8(+) T cell population 6 months after the diagnosis of IM consisted mainly of tetramer(bright)CD8(bright) CD27(+) T cells, suggesting preferential preservation of memory T cells after contraction of the EBV-specific T cell pool.

MeSH Terms
Adolescent Adult CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Epstein-Barr Virus Nuclear Antigens/immunology Flow Cytometry Herpesvirus 4, Human Humans Immunologic Memory Immunophenotyping Infectious Mononucleosis/immunology Interferon-gamma/immunology Lymphocyte Activation Lymphocyte Count Middle Aged T-Lymphocyte Subsets Time Trans-Activators/immunology Tumor Necrosis Factor Receptor Superfamily, Member 7/analysis
Chemicals
BZLF1 protein, Herpesvirus 4, Human Epstein-Barr Virus Nuclear Antigens Trans-Activators Tumor Necrosis Factor Receptor Superfamily, Member 7 Interferon-gamma EBV-encoded nuclear antigen 1
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Scherrenburg J
Department of Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Piriou E R W A N
Nanlohy N M
van Baarle D
References (39)
39 references, click to expand
  1. Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population.
    J Immunol. 2005 Oct 1;175(7):4355-62 PMID: 16177076
  2. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Eur J Immunol. 2005 Mar;35(3):796-805 PMID: 15724243
  3. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.
    Nat Med. 2004 Apr;10(4):406-10 PMID: 15034567
  4. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection.
    J Immunol. 1999 Nov 15;163(10):5735-40 PMID: 10553106
  5. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.
    J Exp Med. 2002 Apr 1;195(7):893-905 PMID: 11927633
  6. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.
    J Exp Med. 2003 Sep 15;198(6):903-11 PMID: 12975456
  7. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
    J Exp Med. 2004 Feb 16;199(4):459-70 PMID: 14769850
  8. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance.
    J Clin Invest. 2005 Sep;115(9):2546-55 PMID: 16110323
  9. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
    Blood. 2005 Nov 1;106(9):3166-74 PMID: 16014568
  10. The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus.
    Viral Immunol. 2003;16(1):3-16 PMID: 12725684
  11. Lineage relationship and protective immunity of memory CD8 T cell subsets.
    Nat Immunol. 2003 Mar;4(3):225-34 PMID: 12563257
  12. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function.
    Eur J Immunol. 2001 Mar;31(3):677-86 PMID: 11241270
  13. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    J Exp Med. 2000 May 15;191(10):1649-60 PMID: 10811859
  14. Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.
    J Infect Dis. 2005 Nov 1;192(9):1513-24 PMID: 16206065
  15. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    J Immunol. 2005 Aug 1;175(3):2010-7 PMID: 16034146
  16. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.
    J Infect Dis. 1997 Oct;176(4):1068-72 PMID: 9333169
  17. Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection.
    J Immunol. 2001 Oct 15;167(8):4450-7 PMID: 11591771
  18. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    J Immunol. 2000 Dec 15;165(12):7078-87 PMID: 11120837
  19. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    J Virol. 2001 Sep;75(18):8649-59 PMID: 11507210
  20. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection.
    J Immunol. 2003 Mar 1;170(5):2590-8 PMID: 12594286
  21. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response.
    J Immunol. 2000 Nov 1;165(9):4831-41 PMID: 11046006
  22. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection.
    AIDS. 2002 Oct 18;16(15):2001-11 PMID: 12370498
  23. The 160,000-Mr virion protein encoded at the right end of the herpesvirus saimiri genome is homologous to the 140,000-Mr membrane antigen encoded at the left end of the Epstein-Barr virus genome.
    J Virol. 1987 Jul;61(7):2063-70 PMID: 3035208
  24. Changes in the composition of circulating CD8+ T cell subsets during acute epstein-barr and human immunodeficiency virus infections in humans.
    J Infect Dis. 2000 Aug;182(2):451-8 PMID: 10915075
  25. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.
    J Exp Med. 1998 May 4;187(9):1395-402 PMID: 9565632
  26. Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.
    Blood. 2007 Feb 1;109(3):1138-46 PMID: 16985171
  27. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient.
    Clin Immunol. 2006 Apr;119(1):16-20 PMID: 16386961
  28. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma.
    J Immunol. 2004 Jun 1;172(11):6931-7 PMID: 15153512
  29. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 PMID: 14688409
  30. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    J Exp Med. 2004 May 17;199(10):1409-20 PMID: 15148339
  31. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 PMID: 9356498
  32. Development of a real-time quantitative assay for detection of Epstein-Barr virus.
    J Clin Microbiol. 2000 Feb;38(2):712-5 PMID: 10655372
  33. CD8(+) T-cell selection, function, and death in the primary immune response in vivo.
    J Clin Invest. 2000 Nov;106(10):1251-61 PMID: 11086026
  34. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection.
    J Immunol. 2005 May 1;174(9):5332-40 PMID: 15843530
  35. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.
    Nat Med. 2002 Apr;8(4):379-85 PMID: 11927944
  36. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Leukemia. 1998 Dec;12(12):2006-14 PMID: 9844931
  37. CD27 and CD57 expression reveals atypical differentiation of human immunodeficiency virus type 1-specific memory CD8+ T cells.
    Clin Vaccine Immunol. 2007 Jan;14(1):74-80 PMID: 17079436
  38. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis.
    Nat Med. 1996 Aug;2(8):906-11 PMID: 8705861
  39. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
    J Infect Dis. 2002 Aug 1;186(3):405-9 PMID: 12134237
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
1365-2249
Published
2008-08-00
Epub
2008-00-28
Pages
231-9
Language
English
Region
England
NLM ID
0057202
PMCID
PMC2492905
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com